# Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

> **NCT04327037** · PHASE1 · COMPLETED · sponsor: **Belarusian Research Center for Pediatric Oncology, Hematology and Immunology** · enrollment: 10 (actual)

## Conditions studied

- Leukemia, Acute Myeloid
- Leukemia, Acute Lymphoblastic

## Interventions

- **BIOLOGICAL:** Expanded Haploidentical Natural Killer cells
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04327037
- **Lead sponsor:** Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-02
- **Primary completion:** 2021-06-06
- **Final completion:** 2021-06-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327037, "Safety of Expanded Haploidentical Natural Killer Cells for Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04327037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*